Next Article in Journal
Can Novel Insights into the Pathogenesis of Myeloproliferative Neoplasm-Related Thrombosis Inform Novel Treatment Approaches?
Previous Article in Journal
A Score for Predicting Freedom from Progression of Children and Adolescents with Hodgkin Lymphoma
Previous Article in Special Issue
On the Shoulders of a Giant: Contributions of Thomas Grogan, MD to Hematopathology
Review

Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy

1
Pathology Department, Instituto de Investigación Sanitaria Fundación Jiménez Díaz, 28029 Madrid, Spain
2
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), 28029 Madrid, Spain
*
Author to whom correspondence should be addressed.
These authors contributed equally to this work.
Academic Editor: Jude Fitzgibbon
Received: 31 March 2021 / Revised: 30 April 2021 / Accepted: 10 May 2021 / Published: 14 May 2021
Diffuse large B-cell lymphomas (DLBCL)s, the most common type of Non-Hodgkin’s Lymphoma, constitute a heterogeneous group of disorders including different disease sites, strikingly diverse molecular features and a profound variability in the clinical behavior. Molecular studies and clinical trials have partially revealed the underlying causes for this variability and have made possible the recognition of some molecular variants susceptible of specific therapeutic approaches. The main histogenetic groups include the germinal center, activated B cells, thymic B cells and terminally differentiated B cells, a basic scheme where the large majority of DLBCL cases can be ascribed. The nodal/extranodal origin, specific mutational changes and microenvironment peculiarities provide additional layers of complexity. Here, we summarize the status of the knowledge and make some specific proposals for addressing the future development of targeted therapy for DLBC cases. View Full-Text
Keywords: large B-cell lymphoma; targeted therapy; molecular classification large B-cell lymphoma; targeted therapy; molecular classification
Show Figures

Graphical abstract

MDPI and ACS Style

Tomas-Roca, L.; Rodriguez, M.; Alonso-Alonso, R.; Rodriguez-Pinilla, S.M.; Piris, M.A. Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. Hemato 2021, 2, 281-304. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2020017

AMA Style

Tomas-Roca L, Rodriguez M, Alonso-Alonso R, Rodriguez-Pinilla SM, Piris MA. Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy. Hemato. 2021; 2(2):281-304. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2020017

Chicago/Turabian Style

Tomas-Roca, Laura, Marta Rodriguez, Ruth Alonso-Alonso, Socorro M. Rodriguez-Pinilla, and Miguel A. Piris 2021. "Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy" Hemato 2, no. 2: 281-304. https://0-doi-org.brum.beds.ac.uk/10.3390/hemato2020017

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop